Clinical trials: Any Cancer
Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
To evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (ASCT) combined with BCMA-CART in the treatment of UHR-MM.
- Conditions
- Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk, Primary Refractory, Early Progression
- Trial name
- NCT07109323
- Testing
- BCMA CART
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Advanced Solid Tumor
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary…
- Trial name
- NCT04762641
- Testing
- ABL503
- Where
- 8 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- ABL Bio, Inc.
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade
Tandem Auto-Allo Transplant for Lymphoma
Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in…
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT01181271
- Testing
- Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant)
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Massachusetts General Hospital
Hormone Receptor Positive Breast Cancer
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal…
- Trial name
- FALCON (NCT01602380)
- Testing
- faslodex 500mg, arimidex 1mg, faslodex dummy
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 462 people
- Sponsor
- AstraZeneca
Stage IV Colorectal Cancer
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
Open label Phase II study of FOLFIRI + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinotecan without any mutation on…
- Trial name
- ULTRA (NCT01704703)
- Testing
- panitumumab, FOLFIRI
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Intracranial Metastatic Disease From Any Solid Malignancy
Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device
Hippocampal-avoidance whole brain radiation therapy (HA-WBRT) limits radiation dose to the hippocampal-avoidance region while still delivering therapeutic doses of radiation to the whole brain.
- Trial name
- NCT05096286
- Testing
- Ethos Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
COVID-19, Invasive Malignancy (Any Type)
COVID-19 and Cancer Consortium Registry
In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt…
- Trial name
- CCC19 (NCT04354701)
- Testing
- Web-based REDCap survey
- Where
- United States
- Volunteers
- 19,275 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
NF type1 With Inoperable Plexiform Neurofibromas
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
This will be an open-label, single-arm, multicenter intermediate access protocol which provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1 (NF1) who have inoperable…
- Trial name
- NCT03259633
- Testing
- Selumetinib
- Where
- United States
- Sponsor
- AstraZeneca
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic…
- Conditions
- Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01217411
- Testing
- Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
The Continuing Care Needs in Colorectal Cancer Patients in Different Stages
The aims of this study are to: 1. explore supportive care needs in colorectal cancer patients with treatment and survivors; 2. compare the supportive care needs in different stage of colorectal cancer; 3.
- Trial name
- NCT00961129
- Where
- Taiwan
- Volunteers
- 269 people
- Sponsor
- National Taiwan University Hospital
Cancer of the Liver, Liver Cancer
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
The working hypothesis is that oral administration of an attenuated strain of Salmonella typhimurium is safe and efficacious for patients with unresectable hepatic metastasis from a solid tumor cancer.
- Conditions
- Cancer of the Liver, Liver Cancer, Hepatoma, Liver Neoplasms
- Trial name
- NCT01099631
- Testing
- Salmonella typhimurium
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Melanoma (Skin)
French Clinical Datbase of Melanoma Patients (RIC-Mel)
With a high incidence, low survival rates and limiter availability of effective treatment, melanoma is one of the research priorities for health authorities.
- Trial name
- RIC-Mel (NCT03315468)
- Where
- France
- Volunteers
- 16,000 people
- Sponsor
- Nantes University Hospital
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
This phase I/II trial is studying how well fludeoxyglucose F 18 PET scan, CT scan, and ferumoxtran-10 MRI scan finds lymph node metastasis before undergoing chemotherapy and radiation therapy in patients with locally advanced…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00416455
- Testing
- fludeoxyglucose F 18, positron emission tomography, computed tomography
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 384 people
- Sponsor
- National Cancer Institute (NCI)
Glioma (Any Grade) in the Brain
Radiolabeled TSPO Targeted Molecular Probe in Glioma
Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium [68Ga]-DOTA-HK-011 in inflammation imaging of glioma.
- Trial name
- NCT07106008
- Volunteers
- 8 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Lung Cancer - Non Small Cell, Lung Metastases From Any Primary
Transbroncheal Novel PDT Peripheral Lung Tumor Ablation With 5-ALA
Photodynamic therapy (PDT) involves the use of special light-sensitive drugs that are selectively absorbed by cancer cells. When exposed to a specific wavelength of light, these drugs are activated within the tumor cells…
- Trial name
- 5ALA-TBPDT (NCT06679712)
- Testing
- Transbronchial PDT lung tumor ablation
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Taoyuan General Hospital
Advanced Solid Tumor
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
This is a first-in-human (FIH) phase 1 open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL501 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary anti-tumor…
- Trial name
- NCT05101109
- Testing
- ABL501
- Where
- 4 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- ABL Bio, Inc.
Breast Cancer
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
The purpose of this study is to understand the safety and effects of the study medicine vepdegestrant (ARV-471/PF-07850327) given together with palbociclib in advanced breast cancer.
- Trial name
- VERITAC-3 (NCT05909397)
- Testing
- Vepdegestrant (ARV-471/PF-07850327), Palbociclib, Letrozole
- Where
- 29 sites in United States, Australia and 8 more
- Volunteers
- 59 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Glioma (Any Grade) in the Brain
18F-Floretyrosine Expanded Access Program
The aim of this Expanded Access Program (EAP) is to enable the use of 18F-Floretyrosine with positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance (PET/MR) imaging to…
- Trial name
- NCT06743100
- Testing
- 18F-Floretyrosine
- Where
- 10 sites in United States
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Solid Tumor, Metastatic Colorectal Cancer
XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
The primary purpose of this study is to find the highest tolerated dose of the study drugs: capecitabine, oxaliplatin, bevacizumab, and dasatinib given in combination to subjects with advanced solid tumors.
- Trial name
- XAD (NCT00920868)
- Testing
- dasatinib, bevacizumab, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Herbert Hurwitz, MD